Tuotteen Kuvaus
SARS-COV2-antigeenin nopea testikortti sisältää kullalla leimatun uuden koronavirus N -proteiinimonoklonaalisen vasta-aineen, joka on esipäällystetty sitoutumistyynylle, ja pariksi yhdistetyn uuden koronaviruksen N-proteiinin monoklonaaliset vasta-aineet, jotka on kiinnitetty testilinjaan (T), ja vastaavat vasta-aineet laadunvalvontalinjassa. (C).
SARS-COV2 Antigen Rapid Test Kit -paketti pystyy havaitsemaan viruksen tartunnan ensimmäisestä vaiheesta (2-3 päivää ennen mahdollisten oireiden alkamista) infektion viimeiseen vaiheeseen (7-10 päivää mahdollisten oireiden alkamisesta).
• Käytetään COVID-19-antigeenin testaamiseen
• Korttimainen muoto, havaitsee viruksen nukleokapsidi (N) -proteiinin.
• Kultaleimatut SARS-CoV-2 N -proteiinimonoklonaaliset vasta-aineet, jotka on immobilisoitu testi-alueelle vastaavien vasta-aineiden kanssa laadunvalvonta-alueella.
• Pyyhkäisyt näytteet nenänielusta tai suunielusta, tuloksena 15 minuuttia.
Tuotteen ominaisuudet
• Tunkeilematon
• Helppo käyttää
• Kätevä, ei tarvita laitteita
• Nopea, saat tuloksen 15 minuutissa
• Vakaa, erittäin tarkasti
• Edullinen, kustannustehokas
SARS CoV-2 RT PCR kit |
|||
| RTq-H731-100R | Bioingentech | 100T | EUR 1311 |
SARS CoV-2 RT PCR kit |
|||
| RTq-H731-150R | Bioingentech | 150T | EUR 1787 |
SARS CoV-2 RT PCR kit |
|||
| RTq-H731-50R | Bioingentech | 50T | EUR 963 |
SARS-CoV-2 IgG ELISA Kit |
|||
| E4901-100 | Biovision | 100 assays | EUR 753 |
Recombinant Coronavirus Nucleoprotein (SARS-CoV-2) |
|||
| P1523-10 | Biovision | 10 µg | EUR 156 |
Recombinant Coronavirus Nucleoprotein (SARS-CoV-2) |
|||
| P1523-50 | Biovision | 50 µg | EUR 551 |
SARS-CoV-2 Spike S2 Peptide |
|||
| 9119P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: (IN) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Spike S2 Peptide |
|||
| 9123P | ProSci | 0.05 mg | EUR 196.25 |
|
Description: (CT) SARS-CoV-2 Spike peptide |
|||
Anti-CoV-2 & SARS-CoV S1 Antibody (Clone# CR3022) |
|||
| A2103-200 | Biovision | 200 µg | EUR 480 |
SARS CoV E Protein |
|||
| abx060650-1mg | Abbexa | 1 mg | EUR 1692 |
SARS CoV Nucleocapsid Protein |
|||
| abx060652-1mg | Abbexa | 1 mg | EUR 1873 |
SARS-CoV Nucleocapsid Protein |
|||
| abx060653-1mg | Abbexa | 1 mg | EUR 1692 |
SARS-CoV Nucleocapsid Protein |
|||
| abx060654-1mg | Abbexa | 1 mg | EUR 1692 |
SARS-CoV Spike Protein |
|||
| abx060655-1mg | Abbexa | 1 mg | EUR 1692 |
SARS-CoV Spike Antibody |
|||
| 3219-002mg | ProSci | 0.02 mg | EUR 171.82 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3219-01mg | ProSci | 0.1 mg | EUR 436.42 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3221-002mg | ProSci | 0.02 mg | EUR 171.82 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3221-01mg | ProSci | 0.1 mg | EUR 436.42 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||